[7] Our findings reinforce current general recommendations that for HIV-positive persons, inactivated vaccines are indicated, and live attenuated vaccines can be considered if severe immunodeficiency (e.g., CD4 <200 cells/mm3 among persons aged 6 years and older [23, 24]) and physical signs of such immunodeficiency are absent; [7, 8] providers might consider obtaining CD4 counts prior to administering live virus vaccines for patients known to be HIV-positive. The gene discussed is CD4; the disease is Immunodeficiency.